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or many bacteria, commitment to surface attachment, and
subsequent growth as a biofilm, is a highly regulated event
(1, 2). Recent work has illuminated the central role of the
intracellular second messenger bis-(3⬘,5⬘)-cyclic dimeric GMP
(c-di-GMP) in controlling surface attachment in many bacterial
systems (3, 4). Although c-di-GMP appears to be a conserved
signal, the outputs it regulates are diverse and vary among
different systems. These outputs include regulation of extracellular polysaccharide production (5, 6), adhesin secretion and
localization (7), flagellar function (6, 8), and transcription of
genes that direct attachment (9). Although c-di-GMP signaling
has been established as a conserved modality in biofilm regulation, the specific mechanisms by which the signal is received
and acted upon are largely unknown.
At least 2 classes of c-di-GMP–binding proteins have been
characterized. The first class, PilZ-domain proteins, has been
linked to regulation of flagellar motility in Enterobacteria,
Vibrio, and Caulobacter (10–12) and to the synthesis of alginate
and type IV pili in Pseudomonas (13, 14). The second class is less
defined but shares an amino acid motif, RxxD, first identified as
the allosteric site of product feedback inhibition in the diguanylate cyclase (DGC) PleD (15). This motif is a common feature
of DGCs but also has been identified in the c-di-GMP–binding
protein PelD (16). Last, the transcription factor FleQ of Pseudomonas aeruginosa was shown recently to bind c-di-GMP (17).
The mechanism by which FleQ binds c-di-GMP remains unknown, and it may represent a third class of effectors.
LapD is an inner-membrane protein required by Pseudomonas
fluorescens for biofilm formation and for maintenance of the
adhesin LapA on the cell surface. In this study we describe LapD
as a c-di-GMP effector protein that binds c-di-GMP via a
degenerate c-di-GMP phosphodiesterase (EAL) domain. Our
analysis indicates that LapD is the c-di-GMP receptor in the
signaling pathway by which inorganic phosphate (Pi) starvation
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0808933106

controls biofilm formation. In contrast to c-di-GMP effectors
identified to date, LapD is an inside-out signaling protein,
communicating cytoplasmic c-di-GMP levels to the membranelocalized attachment machinery via a periplasmic output
domain.
Results
lapD Is Required for Attachment via the LapA Adhesin. P. fluorescens

requires the large adhesin LapA for stable attachment to surfaces (18). Prior work also identified the inner-membrane protein LapD as being required for biofilm formation and suggested
that it played a role in the localization of LapA (Fig. 1A) (19).
To define the effect of lapD on LapA localization, we assessed
the distribution of LapA in the cellular fraction (Cell), cellassociated (CA) fraction, and supernatant fraction (S). The lapD
mutant had decreased cellular levels of LapA compared with
WT (Fig. 1B). Results from an earlier study suggest that this
decrease is not caused by a difference in LapA transcription in
the lapD mutant (19). We also have demonstrated that the
abundance of LapA in the CA fraction is a strong indicator of
a strain’s propensity for biofilm formation (7, 19). Here we see
that the biofilm-defective lapD mutant showed a nearly complete
loss of LapA from the CA fraction (Fig. 1B). Interestingly, this
difference in localization was not caused by a lack of secretion,
because the culture supernatant of ⌬lapD contained 2-fold more
LapA than the WT. Thus it appears that the lapD mutant is
unable to retain the LapA on the cell surface once it has been
secreted (54% ⫾ 2.2% of WT in the cell, 5.7% ⫾ 3.2% in the CA,
and 198% ⫾ 25% for supernatant, n ⫽ 3) (Fig. 1B). Complementation of the lapD mutant with a plasmid carrying lapD
restored WT LapA levels, localization, and biofilm (Fig. 1).
LapD Contains Degenerate and Inactive Diguanylate Cyclase and
c-di-GMP Phosphodiesterase Domains. The amino acid sequence of

LapD contains 3 predicted domains: a HAMP domain, commonly present in transmembrane signaling proteins (20), as well
as diguanylate cyclase (GGDEF) and EAL domains (Fig. 1C).
GGDEF and EAL domain proteins regulate biofilm formation
through c-di-GMP DGC and phosphodiesterase (PDE) activities, respectively (3). Alignment of the LapD protein sequence
with those from empirically verified DGCs and PDEs reveals the
absence of many residues known to be required for catalysis
(supporting information (SI) Fig. S1),. For example, LapD’s
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The second messenger cyclic dimeric GMP (c-di-GMP) regulates
surface attachment and biofilm formation by many bacteria. For
Pseudomonas fluorescens Pf0 –1, c-di-GMP impacts the secretion
and localization of the adhesin LapA, which is absolutely required
for stable surface attachment and biofilm formation by this bacterium. In this study we characterize LapD, a unique c-di-GMP
effector protein that controls biofilm formation by communicating
intracellular c-di-GMP levels to the membrane-localized attachment machinery via its periplasmic domain. LapD contains degenerate and enzymatically inactive diguanylate cyclase and c-di-GMP
phosphodiesterase (EAL) domains and binds to c-di-GMP through
a degenerate EAL domain. We present evidence that LapD utilizes
an inside-out signaling mechanism: binding c-di-GMP in the cytoplasm and communicating this signal to the periplasm via its
periplasmic domain. Furthermore, we show that LapD serves as the
c-di-GMP receptor connecting environmental modulation of intracellular c-di-GMP levels by inorganic phosphate to regulation of
LapA localization and thus surface commitment by P. fluorescens.
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Fig. 1. Biofilm formation and LapA localization phenotypes of the lapD
mutant. (A) Quantitative analysis of biofilm formation by WT plus vector (WT
pvect), ⌬lapD plus vector (pvect), and ⌬lapD plus pLapD (pLapD). (B) Western
blots probed for LapA to analyze adhesin localization profiles for strains
shown in (A). The fractions indicated are cellular (Cell), cell-associated (CA),
and culture supernatant (S). (C) Predicted protein domains of LapD.

GGDEF domain harbors the amino acids RGGEF in the
corresponding positions of this signature motif, replacing an
acidic, catalytic residue with glycine. LapD lacks several critical
EAL domain residues as well, including the glutamic acid of the
EAL motif.
To test if LapD could synthesize or degrade c-di-GMP, a
histidine-tagged form (LapD6H) was purified and tested alongside enzymatically active controls (PleD* and CC3396 of Caulobacter crescentus). We were unable to detect c-di-GMP synthesis or hydrolysis by LapD (Fig. S1), consistent with its
GGDEF and EAL domains being enzymatically inactive. This
result was not caused by interference of the His tag, because
LapD6H can fully complement the ⌬lapD mutation when provided in trans (data not shown).
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Fig. 2. Analysis of c-di-GMP binding by LapD. (A) TLC resolution of [32P]
c-di-GMP co-purified with histidine-tagged proteins. Each reaction contained
50 g of protein unless otherwise indicated. HD ⫽ heat denatured. (B)
Increasing amounts of unlabeled c-di-GMP decrease binding of LapD to [32P]
c-di-GMP (Left), whereas unlabeled GTP does not compete with [32P] c-di-GMP
binding at concentrations up to 1 mM (1000-fold excess) (Right). (C) c-di-GMP
binding by LapD lacking the GGDEF or EAL domain or by the EAL domain
alone. (D) Binding of c-di-GMP to E. coli membranes containing LapD (diamonds) or the ⌬EAL protein (open squares) at increasing concentrations of
ligand. Specific binding (dark squares) is binding to LapD minus binding to
⌬EAL.

LapD Binds c-di-GMP. Degenerate GGDEF or EAL domains have

been proposed to function as regulatory domains through the
binding of c-di-GMP or other nucleotides (15, 25). To test if LapD
could bind c-di-GMP, we evaluated the ability of LapD6H to
interact specifically with this nucleotide. LapD6H and [32P]-cdi-GMP were mixed with Ni-silica resin, the resin was washed,
and the nucleotide was eluted and resolved by TLC. c-di-GMP
bound to LapD in a concentration-dependent manner, at levels
comparable with those of PleDR148A, a known c-di-GMP–binding
protein (Fig. 2A) (15). Little to no c-di-GMP was bound by
heat-denatured protein, resin alone, or an unrelated, histidinetagged protein (PA2934his) (21). The addition of unlabeled
c-di-GMP blocked [32P]-c-di-GMP binding, whereas 1000-fold
excess of GTP had no effect, demonstrating a specific interaction
between LapD and c-di-GMP (Fig. 2B).
To determine which domain(s) of the LapD protein participates in binding c-di-GMP, LapD6H variants lacking the GGDEF (R247-A387) or EAL (H412-G649) domain were tested.
The protein lacking the GGDEF domain was able to bind
c-di-GMP at levels comparable to WT, whereas LapD6H lacking
the EAL domain (⌬EAL) did not show significant binding above
background levels (student’s t test P ⫽ 0.074) (Fig. 2C). Purification of the EAL domain alone (G391-H655) yielded an ⬇30
kD protein capable of binding c-di-GMP as well as, or better
than, the full-length protein (Fig. 2C and data not shown). Taken
together, these data suggest that LapD’s binding activity resides
in the EAL domain.
We further defined the c-di-GMP binding site of LapD by
constructing alanine replacements in candidate residues chosen
for their involvement in substrate binding and their proximity to
the active site of the well-characterized PDE RocR (22). LapD
3462 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0808933106

variants with the mutations K446A, R450A, K581A, and E617A
were stably expressed in the membrane in vivo at WT levels (Fig.
3A). Each mutant protein was purified and tested for c-di-GMP
binding in vitro, and all showed a reduction in binding compared
with the WT protein (Fig. 3B). These alleles also were defective for
complementation of the lapD mutant, indicating that c-di-GMP
binding by LapD is required for biofilm formation (Fig. 3C).
We next tested whether stimulating biofilm formation by
increasing cellular c-di-GMP levels would require binding by
LapD. The DGC(s) that controls attachment via LapD is not
known, so we used a heterologous DGC, PA1107. Expression of
PA1107 boosted biofilm formation by the WT by 82% but had
no effect on a strain with the K446A mutation in LapD (Fig. 3D).
These data are consistent with LapD sensing changes in c-diGMP and show that c-di-GMP binding is required for LapD
function in vivo.
Estimation of LapD’s Dissociation Constant (Kd) for c-di-GMP. To
measure the affinity of membrane-bound LapD for [32P]-c-diGMP, we used a filter-binding assay. The c-di-GMP was mixed
with membranes purified from Escherichia coli overexpressing
either LapD6H or the ⌬EAL protein, and unbound nucleotide
was removed by washing and vacuum filtration. Membranes
containing LapD6H bound c-di-GMP in a concentrationdependent and saturable manner, at levels well above those with
the ⌬EAL protein (Fig. 2D). The specific binding data (binding
of LapD minus binding of ⌬EAL) were analyzed by non-linear
regression, and the Kd of LapD for c-di-GMP was estimated to
be 5.5 ⫾ 2.8 M (n ⫽ 3) (Fig. S2).
Newell et al.
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LapD’s HAMP Domain Modulates Biofilm Formation. The HAMP
domain plays an essential role in many signaling proteins. These
domains typically relay signals across the cytoplasmic membrane, altering their conformation in response to activation of an
extracellular input domain and propagating that conformational
change to a cytoplasmic output domain (20). Structure/function
studies of HAMP-domain proteins have shown that mutations in
this domain can have profound effects, constitutively activating
or inactivating signaling output (23). To investigate a role for this
domain in regulating LapD function, we mutated E203, one of
the few amino acids that are well conserved among all HAMP
domains (24). A non-conservative substitution of this residue,
E203K, led to a loss of biofilm formation as well as a defect in
c-di-GMP binding in vitro (7.5% ⫾ 1% of WT) (Fig. 4A). This
finding shows that the HAMP domain can regulate LapD
function, and it suggests that LapD E203K could be locked in an
inactive conformation that eliminates binding to its ligand and
stimulation of biofilm formation. A conservative substitution at
the same position, E203D, resulted in WT LapD function in
these assays (150% ⫾ 12% of WT c-di-GMP binding) (Fig. 4A).
Both alleles are stably expressed in vivo (Table S1).
To identify more mutations in the HAMP domain that affect
LapD function, we constructed 3 deletions: a short deletion in
each predicted ␣-helix and a deletion of the entire HAMP
domain. Interestingly, deletions in each individual helix, M180A186 (⌬H1) or V207-Q213 (⌬H2), or in the entire HAMP
domain all led to a hyperbiofilm phenotype (Figs. 4A and S3A).
These data demonstrate that the HAMP domain controls
LapD’s effect on biofilm formation and suggest that gross
perturbations to the HAMP structure lead to misregulated,
constitutive output from LapD, resulting in increased biofilm
formation.
A possible explanation for the phenotype of the HAMP
deletion alleles was that these mutations increase LapD’s affinity
for c-di-GMP, and increased c-di-GMP binding could promote
biofilm formation. In our in vitro assay, however, the ⌬H1
protein binds c-di-GMP at levels comparable to WT (94% ⫾ 5%
of WT). If the hyperbiofilm resulting from these HAMP mutations was caused by increased c-di-GMP binding in vivo, we
Newell et al.

Fig. 4. Effects of lapD mutations on biofilm formation and cell-surface LapA
levels. (A) Mutant forms of lapD are compared with pLapD in their ability to
complement ⌬lapD for biofilm formation. (B) Quantification of cell-surface
levels of LapA in the strains in (A) by densitometry on ␣-LapA dot blots (n ⫽ 3,
⫾ SD; representative blots are shown).

reasoned that mutations that block binding would suppress these
effects. Intriguingly, the ⌬H1 R450A double-mutant allele
yielded a hyperbiofilm phenotype but produced a protein that
was unable to bind c-di-GMP in vitro (4.9% ⫾ 5% of WT) (Fig.
4A). Thus the affect of the ⌬H1 mutation on biofilm is not
realized through changes in LapD’s c-di-GMP binding function.
Instead, this mutation must uncouple the necessity of c-di-GMP
binding from LapD’s function in biofilm formation by locking it
in an active state.
Evidence for an Inside-Out Signaling Mechanism. We considered two

models for how LapD may act as a signaling protein. In the first,
LapD receives signals from the periplasm that effect binding of
c-di-GMP in the cytoplasm. This model seemed unlikely, because the hyperbiofilm phenotype of the ⌬H1 mutation in the
HAMP domain is not dependent on c-di-GMP binding. In the
second model, conformational change caused by c-di-GMP
binding/dissociation in the cytoplasm is communicated to the
periplasm through the HAMP domain. If this inside-out mechanism were correct, we hypothesized, then the periplasmic
portion of LapD should be responsible for LapD’s output:
promoting biofilm formation.
To test this hypothesis we expressed the N-terminal portion of
LapD consisting only of the periplasmic domain and both
transmembrane domains (TMD). This protein (pNterm), although unstable, was capable of restoring biofilm formation to
⌬lapD (Fig. S3). We stabilized this LapD variant by fusing it to
␤-galactosidase (␤-gal) after the second TMD. Expression of the
stabilized periplasmic domain (pNterm ⫹ ␤-gal) led to a hyperbiofilm phenotype comparable to that of the ⌬H1 mutation (Fig.
4A). This gain of function relative to WT is consistent with the
output of the periplasmic domain being uncoupled from regulatory input from the cytoplasmic domains. Neither expression
of the entire cytoplasmic portion of LapD nor the EAL domain
alone complemented the lapD mutant (Fig. S3), providing
further evidence that the periplasmic domain is responsible for
LapD’s output.
We identified a mutation in the periplasmic domain, L152P,
that reduces biofilm formation (Fig. 4A). This mutant provided
PNAS 兩 March 3, 2009 兩 vol. 106 兩 no. 9 兩 3463
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Fig. 3. Biochemical and phenotypic analysis of EAL-domain point mutants.
(A) Membrane preparations were assayed for in vivo levels of LapD by Western
blot. (B) c-di-GMP binding by LapD variants and WT LapD. (C) Biofilm assay
performed on ⌬lapD complemented with pLapD or EAL-domain mutants. (D)
Strains with the ⌬lapD, WT, or K446A allele of lapD are compared for biofilm
formation when the DGC PA1107 is expressed.
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an avenue for further testing the necessity of the periplasmic
domain for LapD output and the directionality of LapD signaling. We hypothesized that if this mutation causes impaired
output function, it should suppress the constitutive output that
results from deletions in the HAMP domain. When the L152P
and ⌬H1 mutations were combined, the periplasmic L152P
mutation fully suppressed the hyperbiofilm phenotype of the
HAMP domain mutation (Fig. 4A). These data underscore the
role of the periplasmic domain as the output of LapD signaling
and provide compelling evidence that LapD regulates biofilm
formation via an inside-out signaling mechanism.
The mechanism we propose for LapD signaling depends on
the topology of LapD in the inner membrane. The predicted
topology of LapD was confirmed experimentally by translationally fusing lacZ or phoA to each predicted TMD. Fusing PhoA
in the place of the predicted periplasmic domain yielded an
active phosphatase, whereas a similar fusion in place of the
cytoplasmic domain did not (Fig. S4). The converse was true of
analogous fusions of LapD and ␤-gal, confirming that the
portion of LapD between the 2 TMDs does localize to the
periplasm (Fig. S4).
LapD Regulates Localization of LapA to the Cell Surface. Aberrant

localization of LapA to the culture supernatant from the cell
surface probably is the basis for the lapD mutant’s inability to
form a biofilm (Fig. 1B). To determine if retention of LapA on
the cell is the basis of LapD’s regulation of biofilm formation, the
relative levels of cell-surface LapA on the strains discussed
previously were quantified. In every case, the amount of LapA
on the cells was reflective of a strain’s biofilm phenotype (Figs.
4B and S3B), indicating that LapA localization is regulated by
LapD signaling. Additionally, lapA is required for biofilm formation by strains with lapD hyperbiofilm alleles, consistent with
LapA regulation being sufficient to explain their phenotypes
(data not shown).
LapD’s Role in the Phosphate-Dependent c-di-GMP Signaling Pathway.

We have shown previously that environmental Pi can impact
LapA localization through changes in cellular c-di-GMP levels.
Specifically, the c-di-GMP PDE RapA is expressed in low-Pi
conditions as a member of the Pho regulon. RapA-mediated
reduction in the cellular level of c-di-GMP inhibits retention of
LapA at the cell surface (7). Noting the phenotypic similarities
between Pi starvation and the lapD mutant, and LapD’s regulation of cell-surface LapA levels, we examined LapD’s role in
this environmentally relevant c-di-GMP signaling pathway.
Mutants in the pst system constitutively express the Pho
regulon, including rapA, and are defective for biofilm formation
even in Pi-replete conditions (Fig. 5A) (7). Deletion of rapA
restores biofilm formation to pst mutants (Fig. 5A) (7) and leads
to an increase in cellular c-di-GMP levels in vivo (7). Biofilm
formation by a ⌬pst⌬rapA mutant requires lapD, because a
⌬pst⌬rapA lapD mutant could not form a biofilm, consistent with
LapD’s role as a c-di-GMP receptor in this pathway (Fig. 5A).
We next tested the prediction that constitutively active mutants of LapD should be insensitive to decreases in cellular
c-di-GMP associated with Pho regulon expression. In support of
this hypothesis, the ⌬H1 allele of LapD was epistatic to the pst
mutation, restoring biofilm formation to the pst mutant (Fig.
5A). These data show that a change in LapD structure and
function is sufficient to suppress the effect of constitutive Pho
regulon expression on biofilm formation.
To test how this pathway might function more dynamically, we
examined the effect of physiological Pho regulon induction on
surface attachment by ⌬rapA lapD pLapD, ⌬lapD pLapD, and
⌬lapD p⌬H1, when these strains were starved for Pi. The Pho
regulon is induced after 4 hours of growth in low-Pi medium
(data not shown), and a mutation in rapA partially restores
3464 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0808933106

Fig. 5. The role of LapD in the phosphate-regulated c-di-GMP signaling
pathway. (A) Quantitative assay of biofilm formation by the strains indicated.
(B) Surface attachment by the indicated strains was monitored in high- and
low-Pi media. The percentage of attachment in low-Pi medium relative to
high-Pi medium is given at 0, 60, and 120 min after Pi starvation. (C) Surface
attachment by the indicated strains in high-Pi medium at 0, 60, and 120 min
after ectopic induction of rapA expression (given as a percentage of attachment by the isogenic strain without inducer at each time point).

biofilm formation in low-Pi conditions (7). Before Pho activation, all strains showed a comparable percentage of attachment
in Pi-depleted vs. Pi-replete conditions (Fig. 5B, 0 min). As Pi
starvation ensued, attachment of ⌬lapD pLapD dropped to 17%
of that in the replete condition. Deletion of the PDE rapA
partially restored attachment to 72%, consistent with previous
data (7). The strain carrying the ⌬H1 allele of LapD shows
complete insensitivity to Pi starvation, maintaining the same
level of attachment throughout the course of the assay (Fig. 5B).
To specifically assess the role of c-di-GMP in controlling
attachment, independent of Pi starvation, we ectopically expressed an inducible copy of rapA in the ⌬lapD pLapD and
⌬lapD p⌬H1 backgrounds and monitored attachment in Pireplete media. Induction of rapA was sufficient to decrease
attachment by ⌬lapD pLapD significantly over a 120-min period
to 37% of that by the uninduced control (Fig. 5C). As predicted,
rapA induction had little effect on attachment by ⌬lapD p⌬H1,
demonstrating that the ⌬H1 allele is resistant to the activity of
RapA in vivo. These data, in conjunction with our previous work
(7), describe the pathway by which expression of the Pho regulon
controls surface attachment via LapA: RapA reduces cellular
c-di-GMP levels, and concomitant loss of c-di-GMP binding by
LapD results in loss of LapA from the cell surface.
Discussion
Here we present LapD, a protein with predicted GGDEF and
EAL domains that binds but cannot synthesize or degrade
c-di-GMP. We propose that LapD acts as an effector protein
linking this intracellular signaling molecule to the function of an
extracellular adhesin, LapA, and does so through an inside-out
signaling mechanism (Fig. 6). According to this model, in the
absence of c-di-GMP binding, the conformation of LapD is such
that the HAMP domain represses the periplasmic output. When
LapD binds c-di-GMP, the HAMP domain assumes a conformation that activates the periplasmic output. In vivo and in vitro
Newell et al.
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Fig. 6. A model for inside-out signaling through LapD. (Left) In the absence
of c-di-GMP binding, the periplasmic output is repressed via the HAMP domain. (Right) When c-di-GMP is bound by LapD, the HAMP domain assumes a
conformation that activates output. LapD is depicted as a dimer, because
other HAMP domain proteins are known to be dimers.

analyses of HAMP domain mutants suggest that the ⌬H1 and
E203K mutations lock LapD in the bound and unbound conformations, respectively. Many HAMP-domain proteins have
been shown to transmit extracellular signals into the cell; LapD,
however, has an intracellular input and an extracellular output.
Since the identification of GGDEF and EAL domains and
their enzymatic activities, many proteins containing these domains have been shown to have broad phenotypic effects through
the synthesis and degradation of c-di-GMP (3). In contrast,
relatively few c-di-GMP–binding proteins have been characterized, leaving open the question of how this signal is received and
translated into phenotypic outputs. The occurrence of degenerate GGDEF and EAL domains has led many to speculate that
some are inactive and serve as effectors (15, 25). LapD provides
a key example of an effector protein with degenerate GGDEF
and EAL domains that specifically binds c-di-GMP. Interestingly, it is the EAL domain, and not the GGDEF domain, of
LapD that is necessary for binding. Functional DGCs are known
to bind c-di-GMP as an allosteric inhibitor through the RxxD
motif, but these residues are absent in LapD (Fig. S1 A) (15).
LapD is not the first protein with predicted GGDEF or EAL
domains for which an alternative function has been demonstrated. CsrD of E. coli, GpdS of Staphylococcus epidermidis, and
CdgG of Vibrio cholerae also have functions distinct from their
predicted activities (26–28). Romeo and colleagues have shown
that CsrD does not synthesize or degrade c-di-GMP but instead
binds the regulatory RNAs, CsrB and CsrC (26). The Staphylococcal protein GpdS stimulates biofilm formation but does not
show DGC activity in vitro, nor does it require its GGDEF
domain for its function in vivo (27). Last, CdgG of V. cholerae is
a degenerate and inactive GGDEF-domain protein that requires
the RxxD motif but not the GGDEF motif for its function in
regulating rugosity (28). As Beyhan et al. speculate, CdgG may
be a c-di-GMP–binding protein. These studies, as well as our
work on LapD, highlight the diverse functional potential of
proteins containing these ubiquitous domains.
In P. fluorescens we have shown that environmental Pi is an
important signal governing surface attachment. Among other
effects, this signal impacts cellular c-di-GMP pools through the
PDE RapA (7). Although our previous work indicated that loss
of the LapA adhesin from the cell surface was a key phenotypic
consequence of RapA induction, the mechanism by which
intracellular c-di-GMP levels could affect adhesin localization
remained in question. This study identifies LapD as an important
player in this signaling pathway, binding c-di-GMP in the cytoplasm and communicating this signal to the extracellular machinery of attachment, LapA.
How does LapD control LapA localization? It is possible that
LapD’s periplasmic domain physically stabilizes LapA on the cell
surface by direct interaction or through a protein complex.

Strains and Growth Conditions. Bacteria strains listed in Table S2 were cultured
routinely on lysogeny broth. K10T media were prepared as described (29). E.
coli S17–1 -pir was used for maintenance and conjugal transfer of plasmids.
Yeast strain InvSc1 (Invitrogen) was cultured as described (30). Gentamycin (10
g ml⫺1 for E. coli, 30 g ml⫺1 for Pseudomonas) and kanamycin (30 g ml⫺1)
were used where appropriate.
Static Biofilm Assay. Static biofilm assays were performed and quantified as
described (7) using K10T-1 medium and an incubation time of 6 h. The
quantitative biofilm assay also was used to monitor attachment dynamically
at 4 – 6 h after inoculation using K10T-1 medium as the Pi-replete condition
and K10T- as the low-Pi condition.
LapA Localization Assay. Localization of LapA protein was performed using a
functional HA-tagged variant of LapA as described (7) with minor modifications. Overnight cultures were subcultured in 45 ml of K10T-1 broth for 6 h.
Samples from all fractions were normalized to total protein using the bicinchoninic acid assay (Pierce).
Quantitative LapA Blotting Assay. Bacteria were grown as described for the
LapA localization assay. Aliquots of cultures were pelleted, washed once in
K10T-1 broth, and then resuspended in K10T-1. Cell suspensions were normalized to the OD of the parent culture, serially diluted in K10T-1, and 5-l
aliquots of each dilution were spotted onto a nitrocellulose membrane. After
drying, membranes were probed for LapA as was done for Western blot
analyses (7). Additional controls can be found in the SI Text.
Deletion and Complementation of lapD. A chromosomal deletion of the lapD
reading frame (Pfl01_0131) was constructed with pMQ-LapDKO, a derivative
of allelic exchange vector pMQ83, using established techniques (7). This
mutant lacks bases 142526 –144476 of the annotated P. fluorescens Pf0 –1
genome. The plasmid pLapD, and variants, were used to transform the ⌬lapD
strain by electroporation. Construction of pLapD and variants is described in
the SI Text; primers are listed in Table S3.
Protein Purification. E. coli expressing PleDR148A was obtained from Urs Jenal
(University of Basel, Switzerland), and the protein was purified as described
(15, 31). Purification of LapD6H and variants from E. coli was performed as
previously described (32), with the addition of 1% Triton to all buffers. Protein
purifications ranged from 79% to 96% purity, as determined by SDS PAGE gel
staining and densitometry, and molar concentrations of each protein were
corrected according to relative purity before all assays.
c-di-GMP–Binding Assay. [32P]-c-di-GMP was synthesized as previously described but without HPLC fractionation (31). Binding of [32P]-c-di-GMP to LapD
was assessed by co-purification of the nucleotide with protein bound to a
nickel resin. Each reaction contained 1% Triton X-100, 75 mM Tris pH 8, 150
mM NaCl, 10 mM MgCl2, 1 M c-di-GMP, and 300 pmol of protein in a total
volume of 100 l. After 15-min incubation, 50 l of His-link Ni-silica resin
(Promega) was added and gently agitated for 15 min. Next, resin was pelleted
and washed twice in 150 l of buffer. Nucleotide was eluted by boiling resin
in 20 l of TLC loading buffer and then was fractionated by TLC and quantified
by exposure to a phosphor storage screen as described (7). Binding assays with
cold competitors contained 1 M labeled c-di-GMP for GTP competition and
10 M for c-di-GMP competition. Unlabeled, chemically synthesized c-di-GMP
was obtained from GLSynthesis Inc.
Filter-Binding Assay. E. coli cells were prepared as for protein purification
(described in previous sections). Membranes were purified from the clarified lysate by ultracentrifugation (1 h at 100,000 ⫻ g, 4 °C) and were
resuspended at a concentration of 1 mg protein ml⫺1 in buffer: 75 M Tris
pH 8, 150 mM NaCl, 10 mM MgCl2, and 1 X complete EDTA-free protease
inhibitors (Roche). Western blot analysis on membrane preparations was
performed to confirm the presence of equivalent concentrations of
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Alternatively LapD could regulate LapA function indirectly
through the activity of another protein or proteins in the
periplasm. Further study investigating how LapD functions as a
signaling protein and the precise nature of its output is currently
underway. Uncovering these details will bring us closer to a
complete understanding of how this c-di-GMP signaling pathway
links an environmental signal (Pi) to a complex biological output.

LapD6H and ⌬EAL-6H. Binding reactions contained 50 l of membranes and
[32P]-c-di-GMP at the concentrations indicated. Filtration, washing, and
radiolabel quantification by phosphor storage screen exposure was done
essentially as described (18).

integrated into the chromosome as described in the SI Text. In attachment
assays, rapA expression was induced 4 h after inoculation by the addition of
50 M isopropyl ␤-D-1-thiogalactopyranoside.

Construction and Analysis of Strains with Inducible DGC or PDE. The DGC
PA1107 was expressed from pMQ72 by the addition of 0.018% arabinose in
⌬lapD strains with lapD or K446A reintroduced into the native locus (SI Text).
For PDE expression, rapA (Pfl01_1678) was cloned downstream of Plac to place
it under the control of LacI; this cassette, consisting of lacI-Plac-rapA, was
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